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Asymmetric dimethylarginine is not a good predictor of ischemia
using myocardial perfusion scintigraphy
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Background/aim: Asymmetric dimethylarginine (ADMA) plays role in the pathogenesis of coronary artery disease and related
mortality and morbidity through a number of mechanisms. We hypothesized that plasma ADMA levels would be increased in the
presence of reversible ischemia as measured by GATED single photon emission computed tomography (SPECT) myocardial perfusion
scintigraphy (MPS).
Materials and methods: Fasting i.v. blood samples were drawn before testing. All patients underwent 99mTc-sestamibi GATED SPECT
MPS with a one-day stress-rest protocol; the images were visually analyzed. Post-stress GATED parameters, including ejection fraction,
end systolic and end diastolic volumes, and automatic stress defect scores, were recorded.
Results: The plasma ADMA levels were higher in the ischemic group than in the non-ischemic group (0.46 ± 0.19 vs. 0.40 ± 0.15; P =
0.016). Plasma ADMA levels (odds ratio [OR] = 13.5; 95% confidence interval [CI] = 1.7-109.01; P = 0.015) and sex (OR = 2.49, 95%
CI = 1.18-5.26; P = 0.017) were independent predictors of ischemia. There was no linear correlation between plasma ADMA levels and
both the GATED SPECT and stress test parameters.
Conclusion: Our data support the hypothesis that increased baseline ADMA levels are independently related with the presence of
reversible ischemia.
Key words: Asymmetric dimethylarginine, single photon emission computed tomography, ischemia

1. Introduction
Asymmetric dimethylarginine (ADMA) is an analog
of L-arginine that acts as a nitric oxide (NO) synthesis
inhibitor and contributes to the pathogenesis and related
mortality and morbidity of coronary artery disease (CAD)
(1–3). High levels of ADMA cause atherosclerosis by
triggering endothelial dysfunction through the inhibition
of NO synthesis (4). ADMA also promotes apoptosis,
which inhibits the mobilization and differentiation of
endothelial progenitor cells (5).
Gated single photon emission computed tomography
(SPECT) myocardial perfusion scintigraphy (MPS) is
a highly reliable method for determining the presence
and severity of myocardial ischemia in CAD and can
independently predict the extent of future cardiac events
* Correspondence: melihenginerkan@yahoo.com
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(6–8). To date, there has been only one report comparing
reversible ischemia during stress echocardiography using
the wall motion score with plasma ADMA levels (9). In
this study, we hypothesized that plasma ADMA levels
would be increased in the presence of reversible ischemia
compared to normal subjects using gated SPECT MPS.
2. Materials and methods
2.1. Study population
This study included gated myocardial SPECT images
from 170 consecutive patients [69 (40.6%) males and 101
(59.4%) females; mean age 57 ± 9 years] with ischemia
(n = 87) or no ischemia (n = 83). None of the patients
had cardiac valve disease, cardiomyopathy, malignant
arrhythmias, acute or chronic liver disease, renal failure,
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or suspected pregnancy, and none were breast-feeding at
the time of enrollment. Patients who had a reversible fixed
defect were excluded. Gated SPECT MPS was performed
for the diagnosis of CAD. A detailed history, including
risk factors, current medications, body mass index (BMI),
waist circumference, blood pressure before and after
exercise test, metabolic equivalents, and baseline heart
rate, was collected for all patients. Fasting intravenous
(i.v.) blood samples were drawn before the stress test. All
patients were examined by 99mTc-sestamibi gated SPECT
MPS with a 1-day stress-rest protocol. All subjects gave
informed consent prior to their enrollment in the study,
which was approved by our local ethics committee.
2.2. Imaging protocol
Blood pressure, heart rate, and electrocardiogram findings
were monitored during the test. The test endpoints
included physical exhaustion, anginal complaints,
dyspnea, a significant decrease in blood pressure greater
than 10 mmHg, and achievement of the maximal agerelated heart rate. In patients that could not perform
the treadmill exercise test, a pharmacological stress test
consisting of i.v. adenosine (0.14 mg kg–1 min–1 for 6
min) or dobutamine (up to a maximum dose of 40 µg
kg–1 min–1 in 15 min) was administered until the required
age-related heart rate was reached. Beta-blockers and
calcium antagonists were discontinued for 48 h and longacting nitrates were discontinued for 24 h before gated
myocardial SPECT. Caffeine- and theophylline-containing
foods, medications, and tobacco were discontinued 1 day
before the study. At peak exercise, 296–370 MBq (8–10
mCi) of 99mTc-sestamibi was injected intravenously and
continued for another 1–2 min after the tracer injection.
Resting images were obtained 3–4 h after stress imaging
with an injection that was 3 times the initial dose. Images
were acquired 45 min after the stress-injection and 60
min after the rest-injection with an E.Cam single-headed
gamma camera (Siemens, Germany) equipped with allpurpose high-resolution collimators. The studies were
prefiltered with a Butterworth filter and back-projected
with a ramp filter. After reconstruction, the data were
displayed as tomographic slices and bull’s-eye maps (polar
plots). The images were also visually analyzed. Poststress
gated parameters, including the ejection fraction, end
systolic and end diastolic volumes, and automatic stress
defect scores, were recorded.
2.3. ADMA measurement
Serum specimens were separated from whole blood
samples by centrifugation at 5000 rpm for 10 min and
stored at –20 °C until analysis. Hemolytic and lipemic
serum samples were excluded from the study. All assays
were performed using enzyme-linked immunosorbent
assay kits (BioVendor Research and Diagnostic Products,
Candler, NC, USA) read on a BioTek Epoch (Winooski,
VT, USA) microplate reader. Before the assay, all samples

were brought to room temperature and mixed carefully to
avoid foam development. Standards, controls, and samples
(50 µL) were added to the wells of coated microtiter strips.
Antiserum (50 µL) was added to all wells and mixed on an
orbital shaker. The plate was then covered with adhesive
foil and incubated at 2–8 °C for 20 h. Next, all wells were
washed 4 times with 250 µL of washing buffer. After
removing the residual liquid, 100 µL of enzyme conjugate
was added and the washing process was repeated. The
plates were then incubated for 30 min on an orbital shaker
at room temperature (25 °C). The reaction was stopped by
adding 100 µL of stopping solution. The plates were read
at 450 nm with a reference wavelength of 570 nm. The
standard curve was as predicted and the control results
were in the appropriate ranges.
2.4. Statistical analysis
Statistical analyses were performed using PASW 18
statistical software (SPSS Inc., Chicago, IL, USA). Normality
analyses of continuous variables were performed with
histogram curves. Continuous variables are presented as
mean ± standard deviation. When two groups of data were
compared, we performed an independent sample t-test.
If there were more than two groups, we used one-way
analysis of variance. The Spearman test was performed to
determine the linear correlation between two continuous
variables. Categorical variables were compared between
two groups using a chi-square test and are presented
as frequency and percentage. Receiver operating curve
(ROC) analyses were performed to determine the cut-off
value of ADMA levels for estimating reversible ischemia.
Multivariate logistic regression analyses were performed
to estimate independent predictors of ischemia. Univariate
analyses of variables with P < 0.1 were selected as covariates.
Statistical significance was set at P < 0.05.
3. Results
The characteristics of the patients are presented in Table
1. The plasma ADMA levels were higher in the ischemic
group than in the nonischemic group (0.46 ± 0.19 vs. 0.40
± 0.15; P = 0.016). Male patients had a 2.5-fold higher
frequency of ischemia. The frequencies of beta-blocker,
antiaggregant, and nitrate use were higher in the ischemic
group. In addition, a prior history of revascularization
was more common in the ischemic group. There was no
linear correlation between the plasma ADMA levels and
the gated and stress test parameters (Table 2). We obtained
a sensitivity value of 0.90 and a specificity value of 0.08 for
a cut-off value of 0.19 in ROC analyses (area under the
curve = 0.618; P = 0.008). We found that plasma ADMA
level (odds ratio [OR] =13.5; 95% confidence interval [CI]
= 1.7–109.01; P = 0.015) and sex (OR = 2.49; 95% CI =
1.18–5.26; P = 0.017) were related to ischemia by gated
SPECT MPS when age, sex, plasma ADMA level, and BMI
were used as covariates (Table 3).
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Table 1. Characteristics of the patients.
Nonischemic patients (n = 87)

Ischemic patients (n = 83)

P

Age (years)

57 ± 9

60 ± 9

0.069

Sex (male; n, %)

22 (27)

47 (54)

<0.001

BMI (kg/m )

30.1 ± 4.9

29.5 ± 5.2

0.415

Hypertension (n, %)

54 (65.1)

62 (71.3)

0.385

Diabetes (n, %)

19 (22.9)

21 (24.1)

0.602

Hyperlipidemia (n, %)

31 (37.3)

32 (36.8)

0.939

ADMA (µmol/L)

0.40 ± 0.15

0.46 ± 0.19

0.016

Currently smoking (n, %)

19 (22.9)

27 (31.0)

0.232

Beta blocker

22 (27.5)

41 (47.7)

0.007

Calcium channel blocker

18 (22.5)

13 (15.1)

0.223

Antiaggregant

25 (31.3)

43 (50.0)

0.014

ACE inhibitor

28 (35.0)

25 (29.1)

0.413

Digital

0 (0)

1 (1.2)

0.333

Nitrate

0 (0)

9 (10.5)

0.003

Oral antidiabetic or insulin

12 (14.6)

15 (17.4)

0.620

Antihyperlipidemic

17 (20.7)

25 (29.1)

0.212

2

Medication (n, %)

Prior revascularization (n, %)

9 (30)

21 (70)

0.023

Baseline heart rate (min–1)

80.7 ± 13.0

78.7 ± 12.2

0.327

Systolic blood pressure (mmHg)

122.9 ± 16.4

124.5 ± 14.9

0.510

Diastolic blood pressure (mmHg)

73.3 ± 8.7

74.5 ± 8.0

0.343

Waist circumference (cm)

100.9 ± 10.9

99.7 ± 13.1

0.534

Table 2. Correlations of ADMA levels between both gated and stress parameters.
Plasma ADMA levels
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R

P

Baseline heart rate

–0.088

0.258

Diastolic blood pressure before stress test

0.047

0.547

Systolic blood pressure before stress test

0.036

0.645

Duration of stress test

–0.067

0.400

Metabolic equivalent tasks

–0.188

0.018

Systolic blood pressure after stress test

–0.001

0.993

Diastolic blood pressure after stress test

0.065

0.405

Stress defect score

0.054

0.488

Summed difference score

–0.033

0.673

Ejection fraction

0.033

0.681

End systolic volume

–0.023

0.778

End diastolic volume

–0.008

0.921
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Table 3. Results of multivariate logistic regression analyses where ischemia is the dependent variable.
OR

95% CI for OR

P

Age (years)

0.985

0.941–1.031

0.513

Sex*

2.493

1.180–5.260

0.017

BMI (kg/m2)

0.975

0.899–1.056

0.530

Plasma ADMA (µmol/L)

13.5

1.7–109.01

0.015

Metabolic equivalent tasks

0.878

0.748–1.030

0.110

History of bypass

2.841

0.279–28.972

0.378

Prior revascularization

1.186

0.383–3.671

0.767

Use of beta blocker

2.138

0.907–5.040

0.083

Use of antiaggregant

1.297

0.571–2.942

0.534

Use of nitrate

0.464

0.001– ...

0.999

*Male sex increased 2.5-fold in the ischemic group.

4. Discussion
Our study suggests that plasma ADMA levels are
increased during ischemia and that an increased ADMA
level is a predictor of reversible ischemia. Elevated
plasma concentrations of ADMA have been found in
nonmyocardial infarction heart disease, and clinical
and laboratory studies have reported elevated ADMA
levels in patients diagnosed with ischemic heart disease.
Djordjević et al. (10) reported increased ADMA levels
in ischemic heart disease with median ADMA values of
0.75 (0.31–2.73) µmol/L in stable angina pectoris (SAP)
patients and 0.94 (0.34–3.13) µmol/L in unstable angina
pectoris (USAP) patients, whereas in healthy subjects
the ADMA level was 0.31 (0.17–0.87) µmol/L. The USAP
group displayed 95.65% sensitivity and 96.30% specificity
for ADMA. Cao et al. (11) also showed that ADMA levels
were significantly elevated in acute coronary syndrome
patients compared with controls or SAP patients.
Similarly, Krempl et al. (12) reported that baseline ADMA
concentrations were significantly lower in controls than in
patients with CAD (0.59 ± 0.23 vs. 0.76 ± 0.17 µmol/L),
and that patients with unstable angina had significantly
higher baseline ADMA levels than patients with stable
angina (0.82 ± 0.18 vs. 0.73 ± 0.15 µmol/L). Valkonen et al.
(13) reported that ADMA levels of >0.62 µmol/L resulted
in a 3.9-fold increased risk of acute coronary events in
males. The ADMA level tended to increase in the SAP
group compared to the noncoronary heart disease group,
although the difference was not significant. There are
also studies confirming CAD by percutaneous coronary
angiography. A prospective study (14) showed that the
plasma ADMA level in patients with significant CAD
was notably higher than in the controls (0.66 ± 0.17 and

0.44 ± 0.09 µM, respectively). The same authors used
a larger sample size (n = 997) to confirm these results,
showing that plasma ADMA levels were significantly
higher in patients with significant CAD (0.10 µmol/L)
than in those with insignificant CAD (0.47 ± 0.10 µmol/L)
and normal coronary arteries (0.42 ± 0.08 µmol/L) (15).
In this study, we found that the ADMA level was higher
in ischemic patients than in nonischemic patients and
was independently related to ischemia by multivariate
regression analysis. However, it appears that ADMA is not
a suitable agent for clinical use because of poor diagnostic
accuracy: we calculated 90% sensitivity for a cut-off value
of 0.19 in ROC analyses with a specificity of 0.08.
Significant positive correlations have been
reported between the coronary atherosclerotic score,
which represents the extent and severity of coronary
atherosclerosis, and plasma ADMA levels (r = 0.518)
(14). Song et al. (16) used a multivariate stepwise logistic
regression analysis to show that plasma ADMA levels
were positively correlated with the severity of coronary
atherosclerosis (r = 0.684). Furthermore, single (1.52 ± 0.61
µmol/L), double (1.67 ± 0.80 µmol/L), and multibranched
(2.60 ± 0.62 µmol/L) CAD groups had significantly higher
levels of ADMA than controls. However, we did not detect
a correlation between the baseline plasma ADMA level
and the summed stress and summed difference scores,
which indicate the extent and severity of ischemic heart
disease, respectively.
To date, studies have verified CAD anatomically
by percutaneous coronary intervention, while nuclear
medicine and echocardiographic techniques can evaluate
myocardial function. There is only one study describing the
relationship between ADMA levels and functional status
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of ischemic myocardial tissue (9). This study reported
a significant increase in ADMA in patients with stable
angina and increased wall motion scores after exercise
stress echocardiography. However, this was not related to
stress-induced ischemia. Ours is only the second study to
compare plasma ADMA levels with the functional status
of myocardial tissue, and it is the first to do so using gated
SPECT MPS.

In conclusion, our data support the hypothesis that
increased baseline ADMA levels are independently related
to the presence of ischemia; however, these values are not
suitable for the clinical prediction of ischemia and are
not related to the extent or severity of ischemia, or with
other functional parameters, including poststress ejection
fraction, end systolic volume, and end diastolic volume, in
scintigraphy.
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